Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PPID | Q08752 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686980 | 0.88 | SMYD2 (0.33) | POLBNPSR1CCR1SMYD2CYP3A4 | |
| SCHEMBL13980603 | 0.86 | — | — | |
| SCHEMBL13980734 | 0.80 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4691308 | 0.77 | SMYD2 (0.32) | POLBSMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL4691393 | 0.76 | CYP3A4 (0.32) | CCR1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1843269 | 0.76 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1844316 | 0.76 | SMYD2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL4686577 | 0.76 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL4687092 | 0.75 | SMN1; SMN2 (0.38) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL27564258 | 0.75 | TDP1 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1443046-B1 | NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME | KYORIN SEIYAKU KK (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20080194826-A1 | Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. | 2008-08-14 | — | — | US | disclosed |
| US-20080194826-A1 | Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. | 2008-08-14 | — | — | US | disclosed |
| US-7375115-B2 | 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375115-B2 | 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20050085508-A1 | Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1443046-A1 | NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194826-A1 | Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same | CYP4F2, CYP1A2, CYP4B1 | HSD11B1 816/4885POLB 3628/4885NPSR1 1840/4885 |
| US-20050085508-A1 | Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | OPRM1, OPRD1, HRH4 | HSD11B1 3771/4885POLB 4561/4885NPSR1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.